NCT01598571View on ClinicalTrials.gov

Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy
Interventions
DRUG

Fostamatinib

Fostamatinib 50 mg tablet

DRUG

Fostamatinib

Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose

Trial Locations (1)

Unknown

Ruddington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY